

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad, 500 034, Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602

Email: neuland@neulandlabs.com www.neulandlabs.com

NEULAND LABORATORIES LIMITED

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2014

PART - I

Amount in ₹ Lacs

SI. Particulars No.	Quarter Ended	Quarter Ended	Quarter	Half Year	Half Year	Year
No.		Ended				
			Ended	Ended	Ended	Ended
	30.09.2014		30.09.2013	30.09.2014	30.09.2013	31.03.2014
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from Operations					8	
(a) Net Sales / Income from Operati	ons 11,967.51	9,984.79	10,212.48	21,952.30	21,875.90	45,385.01
(b) Other Operating Income	163.77	2 282.66	215.98	446.38	684.40	1,184.32
Total Income from Operations	(Net) 12,131.23	10,267.45	10,428.46	22,398.68	22,560.30	46,569.33
2 Expenses				-		
(a) Consumption of Raw Materials	6,928.5	1 6,368.23	5,821.10	13,296.74	12,174.03	24,644.22
(b) Changes in inventories of finisher	d goods	(022.25)	(417.94)	(1.024.04)	47.79	12.80
and work in process	(102.59	(922.35)	(417.84)	(1,024.94)	4/./7	000000000000000000000000000000000000000
(c) Employee Benefit Expense	1,227.59	9 1,054.44	891.56	2,282.03	1,855.08	3,625.51
(d) Depreciation	389.90	0 389.90	371.06	779.80	736.24	1,493.86
(e) Manufacturing Expenses	1,600.09	9 1,241.51	1,165.86	2,841.60	2,159.47	4,842.24
(f) Other Expenses	938.70	6 1,165.17	1,580.47	2,103.93	2,948.77	6,506.06
Total Expenses	10,982.26	9,296.90	9,412.21	20,279.16	19,921.38	41,124.69
3 Profit from Operations before Othe Finance Costs and Exceptional Item		970.55	1,016.25	2,119.52	2,638.92	5,444.64
4 Other Income	231.70	73.44	81.30	305.14	153.38	341.48
5 Profit from Ordinary Activities befo	re Finance Costs	1 0 12 00	1 207 55	2 124 66	2 702 20	F 794 12
and Exceptional Items (3+4)	1,380.67	7 1,043.99	1,097.55	2,424.66	2,792.30	5,786.12
6 Finance Costs	629.89	9 567.82	630.69	1,197.71	1,220.74	2,363.76
7 Profit from Ordinary Activities afte	Finance Costs	8 476.17	466.86	1,226.95	1,571.56	3,422.36
but before Exceptional Items (5-6)	750.78	3 4/0.1/	400.00	1,220.73	1,5/1.50	3,422.30
8 Exceptional Items	-		-1	-	-	-
9 Profit from Ordinary Activities befo	re Tax (7-8) 750.78	8 476.17	466.86	1,226.95	1,571.56	3,422.36
10 Tax Expense						
(a) Current tax	178.60		107.70	282.50	318.20	716.70
(b) Deferred Tax	164.6		122.79	338.48	446.39	755.61
(c) MAT Credit entitlement	(107.21			(211.11)	(318.20)	(716.70)
11 Net Profit from Ordinary Activities	after Tax (9-10) 514.74	302.34	344.07	817.08	1,125.17	2,666.75
12 Extraordinary Items	-	-	-	-	-	
13 Net Profit for the period (11-12)	514.74	302.34	344.07	817.08	1,125.17	2,666.75
14 Paid-up Equity Share Capital	772.80	6 772.63	771.56	772.86	771.56	772.63
(Face Value ₹10 per share)	772.0	772.03	771133	,,,,,,,,,	,,,,,,,	
15 Reserves excluding Revaluation Rese	rve as per balance					11,392.57
sheet of previous accounting year						,
16 Earnings per Share (EPS) (in ₹)						
(a) Basic	6.77		4.50	10.67	14.72	34.87
(b) Diluted	6.77	3.95	4.50	10.67	14.71	34.86
		1	1	1 1		





PART - II	PA	RT	-	II
-----------	----	----	---	----

I AIX	AKT - II						
SI.	Particulars	Quarter	Quarter	Quarter	Half Year	Half Year	Year
No.		Ended	Ended	Ended	Ended	Ended	Ended
		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Α	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding			-			
	(a) Number of Shares	38,25,199	38,22,899	38,17,199	38,25,199	38,17,199	38,22,899
	(b) Percentage of Shareholding	49.95%	49.94%	49.93%	49.95%	49.93%	49.94%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total	5.22%	5.22%	5.22%	5.22%	5.22%	5.22%
	shareholding of promoter and promoter group)	3.22/0	3.22/0	J.ZZ/0	3.22/0	3.22/0	3.22/0
	-Percentage of Shares (as a % of the total share	2.61%	2.61%	2.62%	2.61%	2.62%	2.61%
	capital of the Company)	2.01%	2.01%	2.02/	2.01%	2.02/	2.01%
	(b) Non-encumbered						
	-Number of Shares	36,32,779	36,32,779	36,27,779	36,32,779	36,27,779	36,32,779
	-Percentage of Shares (as a % of the total	94.78%	94.78%	94.78%	94.78%	94.78%	94.78%
	shareholding of promoter and promoter group)	94.70%	94.70%	74.70%	74.70%	74.76%	74.70%
	-Percentage of Shares (as a % of the total share	47 440/	47.45%	47.45%	47.44%	47.45%	47.45%
	capital of the Company)	47.44%	47.43%	47.43%	47.44/0	47.43%	47.45%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.09.2014
Pending at the beginning of the quarter	0
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	0

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on October 28, 2014, and approved and taken on record at the Board of Directors meeting held on October 29, 2014.
- 2 EPS for the quarters is not annualised.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard AS 17 "Segment Reporting".
- 4 The Company, vide its Letter of Offer dated September 22, 2014, offered 12,25,276 Equity Shares of Face Value of ₹10 each at a price of ₹204 per Equity Share (including Share Premium of ₹194 per Equity Share) for an amount aggregating to ₹2499.56 lacs to the existing Equity Shareholders of the Company on rights basis in the ratio of 4 fully-paid Equity Shares for every 25 fully-paid Equity Shares held by the Equity Shareholders on the record date i.e. August 14, 2014. The issue opened on September 29, 2014 and closed on October 16, 2014. On October 29, 2014 the Company has allotted 12,22472 Equity Shares, balance Equity Shares being kept in abeyance. The Equity Shares issued vide the said Rights Issue have not been considered for computing Earnings Per Share.





5 The statement of assets and liabilities is as follows:

Amount in ₹ Lacs

		AIII	ount in ₹ Lacs
CI		As on	As on
SI	Particulars	30.09.2014	31.03.2014
No		(Unaudited)	(Audited)
Α	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	772.86	772.63
	(b) Reserves and Surplus	12,207.39	11,487.19
		12,980.25	12,259.82
2	Share Application Money Pending Allotment	5.83	-
3	Non-current Liabilities		
	(a) Long-term Borrowings	4,913.10	3,387.00
	(b) Deferred Tax Liability (Net)	1,364.83	1,026.35
	(c) Other Long-term Liabilities	293.00	293.00
	(d) Long-term Provisions	528.04	513.88
		7,098.97	5,220.23
4	Current Liabilities		
	(a) Short-term Borrowings	14,770.47	14,408.48
	(b) Trade Payables	10,730.25	9,336.80
	(c) Other Current Liabilities	4,625.39	6,167.73
	(d) Short-term Provisions	1,556.17	1,537.11
		31,682.28	31,450.12
	TOTAL	51,767.33	48,930.17
В	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets	16,065.51	16,541.51
	(b) Non-current Investments	764.41	764.41
	(c) Long-term Loans and Advances	2,217.79	2,137.88
	(d) Other Non-current Assets	776.97	745.71
		19,824.68	20,189.51
2	Current Assets		
	(a) Inventories	10,806.56	9,341.74
	(b) Trade Receivables	12,626.76	11,859.20
	(c) Cash and Bank Balances	104.37	28.86
	(d) Short-term Loans and Advances	5,434.98	5,387.00
	(e) Other Current Assets	2,969.98	2,123.86
		31,942.65	28,740.66
	TOTAL	51,767.33	48,930.17

⁶ In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and:

7 Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board For Neuland Laboratories Limited

Dr. D.R.Rao Chairman & Managing Director

Place: Hyderabad

Date: October 29, 2014

i) An amount of ₹98.84 lacs has been adjusted to the opening balance of Reserves & Surplus in respect of those assets where the useful life exhausted as at April 1, 2014

ii) The profit for the quarter and half year has decreased by ₹11.99 lacs and ₹23.98 lacs on account higher depreciation due to application of Schedule II.

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP (Formerly Walker, Chandiok & Co) 7th Floor, Block III, White House Kundan Bagh, Begumpet Hyderabad 500016

T +91 40 6630 8200 F +91 40 6630 8230

Review Report

To the Board of Directors of Neuland Laboratories Limited

- 1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Neuland Laboratories Limited ("the Company") for the quarter ended 30 September 2014 and the year to date results for the period 1 April 2014 to 30 September 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Walker Chandiok & Co LLP

4. The review of financial results for the three months and six months period ended 30 September 2013 included in the Statement was carried out and reported by K.S. Aiyar & Co, Chartered Accountants, vide their unqualified review report dated 8 November 2013 whose review report has been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our review report is not qualified in respect of this matter.

Louiser Chardion & Co LLP

(formerly Walker, Chandiok & Co)

Chartered Accountants

Firm Registration No: 001076N/N500013

per Sanjay Kumar Jain

Partner

Membership No. 207660

Place: Hyderabad Date: 29 October 2014